{"id":67828,"date":"2022-02-24T12:04:28","date_gmt":"2022-02-24T12:04:28","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=87295"},"modified":"2022-02-24T12:04:28","modified_gmt":"2022-02-24T12:04:28","slug":"seegene-unveils-new-assay-optimized-for-on-site-testing-in-living-with-covid-19-era","status":"publish","type":"post","link":"https:\/\/lebanonnewsgazette.com\/seegene-unveils-new-assay-optimized-for-on-site-testing-in-living-with-covid-19-era\/","title":{"rendered":"Seegene unveils new assay optimized for on-site testing in \u2018living with Covid-19\u2019 era"},"content":{"rendered":"
Test can deliver results within 30 minutes, boosting testing capacity up to 5-fold<\/i><\/p>\n
Optimal for on-site testing at large-scale facilities such as schools, airports<\/i><\/p>\n
Accuracy near to RT-PCR tests<\/i> \u00a0even for asymptomatic patients<\/i><\/p>\n
“Reasonable price to allow easy and swift testing for anybody”<\/i><\/p>\n
SEOUL, South Korea, Feb. 24, 2022 \/PRNewswire\/ — Seegene Inc. (KQ 096530),<\/b>\u00a0South Korea’s leading molecular diagnostics company, today, announced the CE-IVD marking of its Allplex\u2122\u00a0SARS-CoV-2 fast MDx Assay.<\/p>\n This new assay is optimized for the ‘living with COVID-19’ era, where mass, swift and cost-efficient testing is vital. The test can deliver results within 30 minutes, the fastest among diagnostics assays developed by Seegene, while matching the accuracy of RT-PCR tests.<\/p>\n Thanks to its cost efficiency, the assay is expected to allow wide-spread access and can be easily used at airports, schools and other large-scale facilities.<\/p>\n Faster Turnaround Times<\/i>: The new test uses an isothermal amplification method that\u00a0does not require a thermal cycler used during the amplification process, thereby reducing the turnaround time. Seegene advanced the isothermal amplification method by utilizing its AI-based assay design system, to specifically target the genes of SARS-CoV-2. By combining such method and Seegene’s applied TOCE\u2122 technology, Allplex\u2122\u00a0SARS-CoV-2 fast MDx Assay delivers highly accurate results within 30 minutes.<\/p>\n Greater Testing Capacity<\/i>: Faster\u00a0turnaround times lead to greater lab testing capacity of up to five times with existing Seegene’s PCR instruments. Increased testing is critical as countries ease Covid-19 restrictions. Mass testing can be the most effective tool for large-scale events and venues such as concerts, airports, schools and stadiums.<\/p>\n High Accuracy<\/i>: The assay can deliver accurate results near RT-PCR tests, even detecting COVID-19 viruses\u00a0from asymptomatic patients.\u00a0In a recent experiment, Seegene’s new assay results agreed with positive results generated through conventional RT-PCR. Rapid antigen tests have been the go-to solution for timely, point-of-care testing. However, its accuracy has been questioned as, in some cases, it can give\u00a0false-negative results, especially for transmissible but asymptomatic patients.<\/p>\n In the coming months, Seegene will allow laboratories to process Allplex\u2122\u00a0SARS-CoV-2 fast MDx Assay using its fully automated MDx system, AIOS. The combination of these two will offer a ‘hands-free’ workflow from extraction to the interpretation of results without manual intervention. This will increase the access to testing at venues where they need fast, accurate and large-scale testing. This assay’s price will also be more economical than standard RT-PCR assays.<\/p>\n “Large-scale on-site testing is more important than ever as many countries decide to live with Covid-19,” said Ho Yi, Seegene’s Chief Sales and Marketing Officer. “The newly developed test can\u00a0provide accurate results and greatly reduce the turnaround time. Seegene will target global markets that require large-scale on-site testing by offering the new test at a reasonable price and will make efforts to normalize daily lives by fostering an environment where anybody can get swiftly tested.”<\/p>\n *TOCE\u2122 technology enables detecting and differentiating multiple targets in a single tube.<\/p>\n